Abstract. In this study, we applied near-infrared fluorescent quantum dots (NIRF-QDs) for non-invasive in vivo and in situ imaging of head and neck squamous cell carcinoma (HNSCC). The U14 squamous cancer cell line with high expression of epidermal growth factor receptor (EGFR) was implanted subcutaneously into the head and neck regions of nude mice to establish HNSCC models. NIRF-QDs with an emission wavelength of 800 nm (NIRF-QD800) were conjugated with EGFR monoclonal antibodies to develop the QD800-EGFR Ab probe. In vivo and in vitro studies demonstrated that the QD800-EGFR Ab probe can specifically bind EGFR expressed on U14 cells. U14 squamous cell carcinoma in the head and neck can be clearly visualized by in vivo imaging after intravenous injection of QD800-EGFR Ab probes. The results suggested that in situ imaging using NIRF-QD-EGFR Ab probes has unique advantages and prospects for the investigation of tumor development, early diagnosis and personalized therapy of HNSCC.
Introduction
Non-invasive in vivo and in situ imaging of tumor cells plays an important role in studying the occurrence and development of cancers, making early diagnosis and conducting personalized therapies. This has been a difficult area due to the lack of highly sensitive imaging substances and specific marker for each particular type of tumor. Quantum dots (QDs) were developed recently and have shown great prospect in the noninvasive imaging of tumors (1, 2) .
QD is a type of nanocrystal composed of elements belonging to Ⅱ-Ⅵ or Ⅲ-Ⅴ groups with a diameter of 2-10 nm. In comparison to the conventional organic fluorescent dyes and fluorescent proteins, QDs have unique optical properties, e.g., broad and continuous distribution of the excitation spectrum, narrow and symmetric emission spectrum, strong fluorescence and high photochemical stability. In addition, QDs are less prone to photobleaching and the spectrum of any points from ultraviolet to the near infrared can be obtained by changing the size and composition of QDs (3, 4) . These optical properties are not owned by all the current fluorescent probes. Currently, QDs have been applied in the imaging of biological macromolecules and cells both in vitro and in vivo (5) (6) (7) . Non-invasive in vivo imaging has been used for the investigation of tumor development (8) (9) (10) , early diagnosis of cancer (10) , the transportation of drugs in vivo (11) , and monitoring of therapeutic responses in vivo (11) (12) (13) . These studies have demonstrated the unique advantages of QDs in the imaging of cells both in vitro and in vivo. Particularly, the recently developed near-infrared fluorescent quantum dot (NIRF-QD) with an emission range of 700-900 nm has the advantage of avoiding the interference of tissue auto fluorescence (400-600 nm). NIRF-QDs have strong tissue penetration, but do not have radiation and are not harmful in vivo. Therefore, NIRF-QDs are extremely suitable for non-invasive in vivo imaging (14, 15) .
NIRF-QDs were conjugated with prostate specific membrane antigen monoclonal antibody (PSMA), Her2 monoclonal antibody and EGF monoclonal antibody, and have been used for non-invasive in vivo imaging of prostate cancer, breast cancer and colon cancer, respectively, in mice (16) (17) (18) . The results from these studies have shown that NIRF-QD probes conjugated with monoclonal antibodies can specifically bind the corresponding antigens expressed by the tumor cells and in vivo imaging can be subsequently obtained. Our previous studies (10) have also shown that in vivo imaging can detect a minimum of 10 4 NIRF-QDs-labeled cancer cells in the presence of skin barrier, which was 100-fold higher than (19, 20) . In this study, we first developed head and neck squamous cell carcinoma model by implanting U14 cells subcutaneously into the chin-neck region of nude mice. We then conjugated EGFR monoclonal antibody to NIRF-QDs with a maximum emission wavelength of 800 nm to produce QD800-EGFR Ab probes. In situ and in vivo imaging of U14 squamous cell carcinoma can be obtained by intravenous injection of QD800-EGFR Ab probes. To our knowledge, this is the first study that EGFR antibody-conjugated NIRF-QDs were utilized for non-invasive in vivo and in situ imaging of head and neck squamous cell carcinoma (HNSCC). The results obtained from these studies provide foundations for the application of NIRF-QDs in vivo imaging, personalized diagnosis and treatment of HNSCC.
Materials and methods
Cell line and animals. The U14 cell line was purchased from the Chinese Academy of Medical Sciences Cancer Institute. The cells were maintained at 37˚C in a humidified atmosphere containing 5% CO 2 in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml of streptomycin. SPF level BALB/c nu/nu nude mice (n=15, age, 6-8 weeks; weigh, 20-25 g) were purchased from the Experimental Animal Center of Chongqing Medical University and were maintained in constant temperature and humidity. Feeds, bedding and water were sterilized. All experimental procedures were approved by the Animal Administration Committee of Chongqing Medical University.
Preparation and purification of QD800-EGFR Ab probes. QD800-EGFR Ab probes were prepared using Qdot ® Antibody Conjugation Kits (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. The first step was the activation and elution of QDs. In this step, 14 µl SMCC at the concentration of 10 mM was mixed with 125 µl QD800 (amine-functionalized CdSeTe/ZnS) at the concentration of 4 µM. After activation at room temperature for 1 h, the mixture was loaded onto NAP-5 column and the colored elution (500 µl) was collected. The second step was antibody reduction and separation. In this step, 6.1 µl DTT (1 M) was added into 300 µl EGFR monoclonal antibody (Abcam, UK) (1 mg/ml in PBS). After 30-min reduction reaction, dye indicator was added and colored solution (500 µl) was obtained by eluting from NAP-5 column. The third step was conjugation and inactivation. In this step, elutions collected in step 1 and 2 were mixed, and after 1-h conjugation, 3 µl 2-mercaptoethanol (10 mM) was added for 30-min inactivation. The final step was concentration and purification. In this step, the inactivated solutions were added into ultrafiltration tube. After 15 min of ultracentrifugation at 7,000 rpm, the conjugated solution was collected from the inner side of the ultrafiltration membrane. The conjugated solution was separated by chromatography and the purified QD800-EGFR Ab probes were obtained. The concentration of QD800-EGFR Ab probes was calculated by the equation: A = εcl, where A represent absorbance, ε represent the extinction coefficient, c represent the molar concentration and l represent the optical path.
The extinction coefficient at 550 nm (ε 550 ) of the purified QD800-EGFR Ab probes was 1.7x10 6 (mol/l)
. Absorbance was measured by UV spectrophotometer (Beckman, DU-600) at 550 nm and the value was 3.442 and the optical path (l) was 1 cm. According to the equation described in Materials and methods, the concentration of the purified QD800-EGFR Ab probes was 2.025 µM.
In vitro labeling of U14 cells by QD800-EGFR Ab probes.
Well-grown U14 cells were inoculated into 9 35-mm glass bottom culture dishes (ø 15 mm) at a concentration of 5x10 4 / dish. After 24 h of culture, the medium was discarded, and the cells were washed with PBS 3 times. The cells were divided into 3 groups. In the experimental group, the cells were added with 100 µl QD800-EGFR Ab probes (100 nM). The cells in the control group Ⅰ were added with 100 µl QD800 (100 nM). The cells in the control group Ⅱ were added with 200 µl EGFR monoclonal antibody (1 µg/ml) to block EGFR. After 2 h of incubation, the cells were washed with PBS 3 times and then added with 100 µl QD800-EGFR Ab probes (100 nM). The cells in each group after addition of QD800-EGFR Ab probes or QD800 were incubated at 37˚C for 30 min followed by 3 washes with PBS. The QD800-EGFR Ab probe-labeled U14 cells were observed under a confocal laser scanning microscope (Leica, TCS-SP5). The following scanning parameters were used: excitation, 405 nm; emission, 750-800 nm; image acquisition size, 1024x1024 pixels; speed, 400 HZ; pinhole size, 135.9 µM; line average, 4; frame average, 1; zoom, 2.0; Scan-Direction, 2; resolution, 8 bits.
Development of HNSCC model in nude mice.
Logarithmic growth phase U14 cells were trypsinized by 0.5% trypsin. After centrifugation at 4˚C (800 rpm) for 4 min, the cells were resuspended in PBS. The suspension containing 2x10 6 U14 cells were injected subcutaneously into the chin-neck junction area of 15 nude mice to establish the HNSCC model. Tumor growth was observed daily and the experiment started when the maximum diameter of the tumor reached 0.8-1.2 cm.
In vivo imaging of the tumors. The mice with tumors were divided into experimental group, control group Ⅰ and control group Ⅱ with 5 mice in each group. After anesthesia by intraperitoneal injection of 2% sodium pentobarbital (40 mg/kg), each mouse in the experimental group was injected with 100 µl QD800-EGFR Ab probes containing 100 pmol equivalent of QD800 via the tail vein. For the control group Ⅰ, each mouse was injected with 100 µl of QD800 containing 100 pmol equivalent of QD800 via the tail vein. Each mouse in the control group Ⅱ was injected with 250 µl EGFR monoclonal antibody (1 mg/ml) to block EGFR. After 24 h, the mice were injected with 100 µl QD800-EGFR Ab probe containing 100 pmol equivalent of QD800 via the tail vein. In vivo imaging was conducted for all the animals after 30 min, 1, 3, 6, 9 and 24 h of injection of the QD800-EGFR Ab probes or QD800 using Maestro In Vivo imaging system (CRI). Excitation/emission wavelength was 630/800 nm, the exposure time was 50 ms and the acquisition time was 10 sec with a binning of 2x2 and pixels of 1024x1024. All the images were processed and the data were analyzed by Maestro2.10.0 software. Auto-and the target-fluorescence were detected and each signal was assigned with a pseudo-color. Auto-fluorescence in this study was set to green color and the target signal was set to red color. Finally, overlay of the two color images were used for analysis.
Cellular and histological examination of the U14 tumors. Two mice from the experimental group, control group Ⅰ and control groups Ⅱ, respectively, were euthanized 6 h after injection of QD800-EGFR Ab probe and QD800. The remaining 3 mice from the experimental and control groups were euthanized 24 h after of QD800-EGFR Ab probe injection. The subcutaneous neck tumors were excised and embedded in Optimal Cutting Temperature compound. The embedded samples were frozen and cryo-sections with a thickness of 7 µm were continuously cut at -20˚C. One of every two continuous sections was stained with hematoxylin and eosin (H&E) for observation of the tumor growth. The other section was used for confocal microscopy analysis to observe the distribution of QD800 in the tissues. Confocal parameter settings were the same as described above.
Statistical analysis. Statistical analysis was performed using paired and unpaired Student's t-tests for comparisons between and within groups, respectively. Statistical significance was established at the level of P<0.05. Data are presented as the means ± SE.
Results

In vitro labeling of U14 cells by QD800-EGFR Ab probes.
Red fluorescence of QD800 was observed on the membrane of U14 cells in the experimental group (Fig. 1A) . In contrast, fluorescence was not observed in the cells of control group Ⅰ or control group Ⅱ (Fig. 1B and C) , suggesting that QD800 does not bind U14 cells, while QD800-EGFR Ab probes can bind U14 cells. In addition, QD800-EGFR Ab probes did not bind U14 cells that had been blocked by EGFR monoclonal antibody. These results demonstrated that the immunological activity of EGFR Ab was maintained after conjugation with QD800 and could specifically recognize EGFR expressed on the surface of U14 cells, leading to the attachment of QD800 to the cell surface. 
. In vivo imaging of tumors by QD800-EGFR Ab probes at different times points. (A)
In vivo images of U14 squamous cell carcinoma mice after intravenous injection with QD800-EGFR Ab probe in the experimental group; (B) in vivo images of U14 squamous cell carcinoma mice after intravenous injection with 100 pmol QD800 in the control groupⅠ; (C) in vivo images of U14 squamous cell carcinoma mice in the control group II, the mice were injected with 250 µl EGFR monoclonal antibody (1 mg/ml) and 24 h later the mice were injected with 100 l QD800-EGFR Ab probes containing 100 pmol equivalent of QD800; (D) the changes of the signal-to-noise ratio at different time points after injection of the probe for in vivo imaging of U14 squamous cell carcinoma in the experimental group. In vivo imaging of tumors. Significant tumor growth was observed 1 week after inoculation with U14 cells in the chinneck junction area of nude mice. Tumors developed in all the 15 nude mice. Two weeks after inoculation, the maximum diameter of the tumors reached 0.8-1.2 cm and at this time point we started the imaging experiment. The tumor sites of mice in the experimental group showed significant fluorescent signals 30 min after injection of QD800-EGFR Ab probes via the tail vein. The most complete fluorescent signals were observed after 30 min to 6 h of probe injection and the size of the fluorescent images corresponded to that of the tumors. The size of the fluorescent images was significantly reduced after 9 h of probe injection and the fluorescent images were minimal after 24 h of probe injection (Fig. 2A) . The signal-tonoise ratio (the fluorescence intensity ratio between tumor and background) was relatively high from 30 min to 6 h after probe injection. The signal-to-noise ratio was significantly decreased at 9 h and was close to the baseline level at 24 h after probe injection (Fig. 2D) . In the control group Ⅰ and control group Ⅱ, fluorescent signals were not detected at the tumor sites after 30 min to 24 h of probe injection (Fig. 2B and C) .
Cellular and histological examination of the U14 tumors.
H&E staining of the tumor sections from the mice after 6 h and 24 h of probe injection showed that there were large amount of cancer cells in the tumors of both experimental and control groups, suggesting that tumors were well developed (Fig. 3) . Confocal microscopy analysis of the cryo-sections confirmed that QD800 fluorescence signal was not detected in the tumor section of mice in the control group Ⅰ and control group Ⅱ after 6 h and 24 h of injection. In contrast, in the experimental group, large amount of QD800 was accumulated in the tumor section of mice after 6 h of injection. QD800 was scattered in the tumor section of mice after 24 h of injection (Fig. 4) . 
Discussion
Direct in vivo and in situ imaging of cancer cells is one of the key technologies for investigation of tumor development, early diagnosis, drug screening and personalized treatment (9, 10, 21, 22) . In comparison to the existing organic fluorescent dyes and fluorescent proteins, QDs have excellent optical properties, e.g., high light stability and high fluorescence quantum yields. Particularly, NIRF-QDs have excellent tissue penetration and great prospects for non-invasive in vivo imaging of the cancer cells (1-4) . Previous studies have demonstrated that QDs at the experimental concentration are not cytotoxic and do not affect the growth and differentiation of the live cells (3, 4, 23) . Our previous studies have also shown that labeling of cancer cells with NIRF-QDs do not affect their growth, proliferation, apoptosis, invasion, metastasis or the ability to form tumors (10, (24) (25) (26) . Clinically, optical examination is a safe, simple and economical approach (18, 27) . In addition to the unique optical properties as described earlier. QDs, as nanoparticles, have an easily modified surface, can be connected to variety of biological molecules and can easily penetrate tumor angiogenesis and reach the cancer cells (10, (16) (17) (18) . Therefore, QDs have shown unique advantages for non-invasive in vivo imaging of cancers.
One of the difficult problems in surgical treatment is how to correctly identify the tumor boundary and determine the scope of tailored surgical resection for different patients to improve their survival rate and quality of life. Since there is no method for direct visualization of cancer cells during surgery, clinicians determine the surgery boundary by experience and the alteration of the cancer tissue texture, which leads to a failure rate of as high as 40% in patients with complete removal of head and neck cancer surgery (28, 29) and greatly affects the patients' survival rate. Therefore developing methods by which clinicians could monitor cancer cells in real time during surgery and perform individual tailored surgical resection is one of the key technologies to improve survival. In this study, we implanted U14 squamous cancer cells with high expression of EGFR into the head and neck sites of nude mice for in vivo imaging studies. This was due: 1), most of the malignant tumors in the head and neck regions are squamous cell carcinoma and 90% of the squamous cancer cells highly express EGFR (30, 31) . Therefore, QD in vivo imaging by targeting EGFR has broad applicability for HNSCC; 2), targeting of EGFR antibody-conjugated QDs (a kind of nano-probe) to the tumors after intravenous injection is closely related to the location of the tumors and currently there are no reports with regard to the QDs in vivo imaging of head and neck tumors.
In this study, we conjugated NIRF-QDs with EGFR monoclonal antibody to produce QD800-EGFR Ab probes. Our results demonstrated that QD800-EGFR Ab probes can specifically bind U14 squamous cancer cells both in vivo and in vitro and produce clear images of head-neck tumors. Imaging of U14 squamous cell carcinoma by QD800-EGFR Ab probes is achieved by both active and passive targeting (18, 32) . The tumor is rich in angiogenesis. The basal membrane of tumor angiogenesis is incomplete or lacking and there are wide gaps between the endothelial cells. The presence of these gaps results in the passive targeting of the QD800-EGFR Ab probes into the tumor tissues through the highly permeable tumor angiogenesis. Specific antigen-antibody binding leads to the active targeting of QD800-EGFR Ab probes to the EGFR on cell surface. Thus, EGFR Ab acts as a bridge to connect QD800 to the cells. Our studies showed that the bright and complete fluorescence images are not significantly changed from 30 min to 6 h in the experimental group after intravenous injection of QD800-EGFR Ab probes. However, the size and intensity of the fluorescence images are significantly decreased after 9 h of probe injection, indicating that the best time for imaging of HNSCC by QD800-EGFR Ab probes is from 30 min to 6 h after intravenous injection of the probes. After 24 h of probe injection, the images of the tumors are further reduced and the intensity of fluorescence is decreased. This might be due to the gradual degradation of ligands and coating layer on the surface of probe by lysosomal enzymes (18, 32, 33) , leading to gradual decreases of the probe binding ability and gradual quenching of the fluorescent quantum dots. Our previous studies (10) have also shown that in vivo imaging can detect a minimum of 10 4 cancer cells labeled with NIRF-QDs in the presence of skin barrier, which was 100-fold higher than the minimal detection limit of CT and MRI. In addition, the sensitivity can be further enhanced when the tumor is exposed during surgery. Gao et al predicted (32) that in vivo imaging can detect as low as 10-100 QDs-labeled cancer cells. In this study, toxicity of the ODs in the mice was not observed.
This study demonstrates that intravenous injection of QD800-EGFR Ab probes can produce clear in vivo and in situ images of HNSCC with high expression of EGFR. QD800-EGFR Ab probes have shown great potential in the investigation of tumor development, early diagnosis and its individual tailored surgical resection. Previous studies have suggested that biologically functionalized QDs have excellent biological compatible and are water soluble (3, 4, 23) . In addition, they do not cause side effects on live subjects and do not affect cellular growth, differentiation and function within the range of experimental doses (3, 4, 10, (23) (24) (25) (26) . However, the core of QDs is typically made up of heavy metal elements, e.g., plutonium, cadmium and mercury. These metal elements are toxic when they are released. Though the toxicity of these QDs can be reduced by using core-shell structure, long-term in vivo biological oxidation and degradation may cause QD shell shedding, which can lead to the release of heavy metal ion and subsequent toxic action (34) . Therefore, the studies of replacing plutonium, cadmium or mercury with other elements to produce non-toxic QDs or speeding up excretion of QDs from body are important directions for future investigations.
